Highly increased risk of fracture in patients with myeloproliferative neoplasm

Data from a retrospective analysis of 10,752 Swedish patients with myeloproliferative neoplasms (MPNs) demonstrated a significantly increased risk of bone fractures among these patients, compared with the overall population. Based on hip fracture incidence for the entire Swedish population, the observed-to-expected number of hip fractures for all patients with an MPN, polycythemia vera, essential thrombocythemia, and MPN undetermined were 1.20 (95% CI, 1.10-1.31), 1.37 (95% CI, 1.19-1.58), 1.02 (95% CI, 0.87-1.19), and 1.28 (95% CI, 1.07-1.52) respectively.